{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:59:03Z","timestamp":1790391543918,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"DOI":"10.1038\/s41416-026-03618-4","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:02:22Z","timestamp":1790344942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of GC001: an oncolytic vaccinia virus expressing STRIP1 shRNA"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2997-2511","authenticated-orcid":false,"given":"Gongchu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaohui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheqi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jili","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchao","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3660-0249","authenticated-orcid":false,"given":"Yunshan","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"3618_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd.2016.178","volume":"15","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2016;15:660. https:\/\/doi.org\/10.1038\/nrd.2016.178.","journal-title":"Nat Rev Drug Discov"},{"key":"3618_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10358","volume":"477","author":"CJ Breitbach","year":"2011","unstructured":"Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99\u2013102. https:\/\/doi.org\/10.1038\/nature10358.","journal-title":"Nature"},{"key":"3618_CR3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","volume":"3","author":"SE Lawler","year":"2017","unstructured":"Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3:841\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2064.","journal-title":"JAMA Oncol"},{"key":"3618_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2174\/156800907780058817","volume":"7","author":"W Yu","year":"2007","unstructured":"Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets. 2007;7:141\u20138. https:\/\/doi.org\/10.2174\/156800907780058817.","journal-title":"Curr Cancer Drug Targets"},{"key":"3618_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160\u201377. https:\/\/doi.org\/10.1038\/s41571-022-00719-w.","journal-title":"Nat Rev Clin Oncol"},{"key":"3618_CR6","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28:1630\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01897-x.","journal-title":"Nat Med"},{"key":"3618_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43856-022-00098-4","volume":"2","author":"SJ Russell","year":"2022","unstructured":"Russell SJ, Bell JC, Engeland CE, McFadden G. Advances in oncolytic virotherapy. Commun Med. 2022;2:33. https:\/\/doi.org\/10.1038\/s43856-022-00098-4.","journal-title":"Commun Med"},{"key":"3618_CR8","doi-asserted-by":"publisher","first-page":"921534","DOI":"10.3389\/fcimb.2022.921534","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, Oduro PK, Guo R, Li R, Leng L, Kong X, et al. Oncolytic viruses: immunotherapy drugs for gastrointestinal malignant tumors. Front Cell Infect Microbiol. 2022;12:921534. https:\/\/doi.org\/10.3389\/fcimb.2022.921534.","journal-title":"Front Cell Infect Microbiol"},{"key":"3618_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","volume":"7","author":"ZS Guo","year":"2019","unstructured":"Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7:6. https:\/\/doi.org\/10.1186\/s40425-018-0495-7.","journal-title":"J Immunother Cancer"},{"key":"3618_CR10","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1158\/1535-7163.Mct-20-0863","volume":"20","author":"T Inoue","year":"2021","unstructured":"Inoue T, Byrne T, Inoue M, Tait ME, Wall P, Wang A, et al. Oncolytic vaccinia virus gene modification and cytokine expression effects on tumor infection, immune response, and killing. Mol Cancer Ther. 2021;20:1481\u201394. https:\/\/doi.org\/10.1158\/1535-7163.Mct-20-0863.","journal-title":"Mol Cancer Ther"},{"key":"3618_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/14712598.2020.1757066","volume":"20","author":"A Pelin","year":"2020","unstructured":"Pelin A, Boulton S, Tamming LA, Bell JC, Singaravelu R. Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. Expert Opin Biol Ther. 2020;20:1083\u201397. https:\/\/doi.org\/10.1080\/14712598.2020.1757066.","journal-title":"Expert Opin Biol Ther"},{"key":"3618_CR12","first-page":"8751","volume":"61","author":"JA McCart","year":"2001","unstructured":"McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61:8751\u20137.","journal-title":"Cancer Res"},{"key":"3618_CR13","doi-asserted-by":"publisher","first-page":"200823","DOI":"10.1016\/j.omton.2024.200823","volume":"32","author":"C Gao","year":"2024","unstructured":"Gao C, Ying Q, Qiu Y, Ren N, Chen K, Zhou Y, et al. Oncolytic vaccinia virus harboring CLEC2A gene enhances viral replication and antitumor efficacy. Mol Ther Oncol. 2024;32:200823. https:\/\/doi.org\/10.1016\/j.omton.2024.200823.","journal-title":"Mol Ther Oncol"},{"key":"3618_CR14","doi-asserted-by":"publisher","first-page":"200878","DOI":"10.1016\/j.omton.2024.200878","volume":"32","author":"J Yu","year":"2024","unstructured":"Yu J, An N, Zhu J, Zhu B, Zhang G, Chen K, et al. AVL-armed oncolytic vaccinia virus promotes viral replication and boosts antitumor immunity via increasing ROS levels in pancreatic cancer. Mol Ther Oncol. 2024;32:200878. https:\/\/doi.org\/10.1016\/j.omton.2024.200878.","journal-title":"Mol Ther Oncol"},{"key":"3618_CR15","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1089\/hum.2024.100","volume":"35","author":"B Zhu","year":"2024","unstructured":"Zhu B, Hong Z, Zhu J, Yu J, Zhou Y, Chen K, et al. Oncolytic vaccinia virus encoding aphrocallistes vastus lectin suppresses the proliferation of gastric cancer cells. Hum Gene Ther. 2024;35:938\u201350. https:\/\/doi.org\/10.1089\/hum.2024.100.","journal-title":"Hum Gene Ther"},{"key":"3618_CR16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ijc.35209","volume":"156","author":"R Wang","year":"2025","unstructured":"Wang R, Hu M, Lozzi I, Jin CZJ, Ma D, Splith K, et al. Cytokine-armed vaccinia virus promotes cytotoxicity toward pancreatic carcinoma cells via activation of human intermediary CD56(dim)CD16(dim) natural killer cells. Int J Cancer. 2025;156:638\u201351. https:\/\/doi.org\/10.1002\/ijc.35209.","journal-title":"Int J Cancer"},{"key":"3618_CR17","doi-asserted-by":"publisher","unstructured":"Azar F, Deforges J, Demeusoit C, Kleinpeter P, Remy C, Silvestre N, et al. TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment. J Immunother Cancer. 2024; 12. https:\/\/doi.org\/10.1136\/jitc-2024-009302","DOI":"10.1136\/jitc-2024-009302"},{"key":"3618_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.omto.2020.11.002","volume":"20","author":"N Wang","year":"2021","unstructured":"Wang N, Wang J, Zhang Z, Cao H, Yan W, Chu Y, et al. A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer. Mol Ther Oncolytics. 2021;20:71\u201381. https:\/\/doi.org\/10.1016\/j.omto.2020.11.002.","journal-title":"Mol Ther Oncolytics"},{"key":"3618_CR19","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.7150\/thno.56494","volume":"11","author":"L Chen","year":"2021","unstructured":"Chen L, Chen H, Ye J, Ge Y, Wang H, Dai E, et al. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. Theranostics. 2021;11:6668\u201381. https:\/\/doi.org\/10.7150\/thno.56494.","journal-title":"Theranostics"},{"key":"3618_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/mt.2011.276","volume":"20","author":"KA Parato","year":"2012","unstructured":"Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther J Am Soc Gene Ther. 2012;20:749\u201358. https:\/\/doi.org\/10.1038\/mt.2011.276.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"3618_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18:689\u2013706. https:\/\/doi.org\/10.1038\/s41573-019-0029-0.","journal-title":"Nat Rev Drug Discov"},{"key":"3618_CR22","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1172\/jci122287","volume":"129","author":"J Martinez-Quintanilla","year":"2019","unstructured":"Martinez-Quintanilla J, Seah I, Chua M, Shah K. Oncolytic viruses: overcoming translational challenges. J Clin Investig. 2019;129:1407\u201318. https:\/\/doi.org\/10.1172\/jci122287.","journal-title":"J Clin Investig"},{"key":"3618_CR23","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/mt.2016.101","volume":"24","author":"S Downs-Canner","year":"2016","unstructured":"Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O\u2019Malley ME, Jones HL, et al. Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol Ther J Am Soc Gene Ther. 2016;24:1492\u2013501. https:\/\/doi.org\/10.1038\/mt.2016.101.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"3618_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.biocel.2013.11.021","volume":"47","author":"J Hwang","year":"2014","unstructured":"Hwang J, Pallas DC. STRIPAK complexes: structure, biological function, and involvement in human diseases. Int J Biochem cell Biol. 2014;47:118\u201348. https:\/\/doi.org\/10.1016\/j.biocel.2013.11.021.","journal-title":"Int J Biochem cell Biol"},{"key":"3618_CR25","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1038\/onc.2016.9","volume":"35","author":"Z Shi","year":"2016","unstructured":"Shi Z, Jiao S, Zhou Z. STRIPAK complexes in cell signaling and cancer. Oncogene. 2016;35:4549\u201357. https:\/\/doi.org\/10.1038\/onc.2016.9.","journal-title":"Oncogene"},{"key":"3618_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41594-021-00564-y","volume":"28","author":"BC Jeong","year":"2021","unstructured":"Jeong BC, Bae SJ, Ni L, Zhang X, Bai XC, Luo X. Cryo-EM structure of the Hippo signaling integrator human STRIPAK. Nat Struct Mol Biol. 2021;28:290\u20139. https:\/\/doi.org\/10.1038\/s41594-021-00564-y.","journal-title":"Nat Struct Mol Biol"},{"key":"3618_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/ncb3083","volume":"17","author":"CD Madsen","year":"2015","unstructured":"Madsen CD, Hooper S, Tozluoglu M, Bruckbauer A, Fletcher G, Erler JT, et al. STRIPAK components determine mode of cancer cell migration and metastasis. Nat Cell Biol. 2015;17:68\u201380. https:\/\/doi.org\/10.1038\/ncb3083.","journal-title":"Nat Cell Biol"},{"key":"3618_CR28","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1111\/bph.14795","volume":"176","author":"E Triastuti","year":"2019","unstructured":"Triastuti E, Nugroho AB, Zi M, Prehar S, Kohar YS, Bui TA, et al. Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU-MP-1, protects the heart against adverse effects during pressure overload. Br J Pharmacol. 2019;176:3956\u201371. https:\/\/doi.org\/10.1111\/bph.14795.","journal-title":"Br J Pharmacol"},{"key":"3618_CR29","doi-asserted-by":"publisher","first-page":"101233","DOI":"10.1016\/j.redox.2019.101233","volume":"26","author":"Y Wang","year":"2019","unstructured":"Wang Y, Li J, Gao Y, Luo Y, Luo H, Wang L, et al. Hippo kinases regulate cell junctions to inhibit tumor metastasis in response to oxidative stress. Redox Biol. 2019;26:101233. https:\/\/doi.org\/10.1016\/j.redox.2019.101233.","journal-title":"Redox Biol"},{"key":"3618_CR30","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.ymthe.2020.03.014","volume":"28","author":"BE Kennedy","year":"2020","unstructured":"Kennedy BE, Sadek M, Gujar SA. Targeted metabolic reprogramming to improve the efficacy of oncolytic virus therapy. Mol Ther J Am Soc Gene Ther. 2020;28:1417\u201321. https:\/\/doi.org\/10.1016\/j.ymthe.2020.03.014.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"3618_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2049-3002-2-4","volume":"2","author":"SD Stuart","year":"2014","unstructured":"Stuart SD, Schauble A, Gupta S, Kennedy AD, Keppler BR, Bingham PM, et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014;2:4 https:\/\/doi.org\/10.1186\/2049-3002-2-4.","journal-title":"Cancer Metab"},{"key":"3618_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","volume":"20","author":"J Rehwinkel","year":"2020","unstructured":"Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20:537\u201351. https:\/\/doi.org\/10.1038\/s41577-020-0288-3.","journal-title":"Nat Rev Immunol"},{"key":"3618_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.Cd-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26\u201339. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-0761.","journal-title":"Cancer Discov"},{"key":"3618_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","volume":"38","author":"JD Hayes","year":"2020","unstructured":"Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer cell. 2020;38:167\u201397. https:\/\/doi.org\/10.1016\/j.ccell.2020.06.001.","journal-title":"Cancer cell"},{"key":"3618_CR35","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10571-015-0166-x","volume":"35","author":"L Li","year":"2015","unstructured":"Li L, Tan J, Miao Y, Lei P, Zhang Q. ROS and autophagy: interactions and molecular regulatory mechanisms. Cell Mol Neurobiol. 2015;35:615\u201321. https:\/\/doi.org\/10.1007\/s10571-015-0166-x.","journal-title":"Cell Mol Neurobiol"},{"key":"3618_CR36","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.devcel.2019.06.003","volume":"50","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Pan D. The Hippo signaling pathway in development and disease. Dev cell. 2019;50:264\u201382. https:\/\/doi.org\/10.1016\/j.devcel.2019.06.003.","journal-title":"Dev cell"},{"key":"3618_CR37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","volume":"88","author":"S Ma","year":"2019","unstructured":"Ma S, Meng Z, Chen R, Guan KL. The Hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019;88:577\u2013604. https:\/\/doi.org\/10.1146\/annurev-biochem-013118-111829.","journal-title":"Annu Rev Biochem"},{"key":"3618_CR38","doi-asserted-by":"publisher","first-page":"e1010505","DOI":"10.1371\/journal.ppat.1010505","volume":"18","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhang X, Lei X, Wang H, Jiang J, Wang Y, et al. Influenza A virus NS1 protein hijacks YAP\/TAZ to suppress TLR3-mediated innate immune response. PLoS Pathog. 2022;18:e1010505. https:\/\/doi.org\/10.1371\/journal.ppat.1010505.","journal-title":"PLoS Pathog"},{"key":"3618_CR39","doi-asserted-by":"publisher","first-page":"e1011007","DOI":"10.1371\/journal.ppat.1011007","volume":"18","author":"JH Lee","year":"2022","unstructured":"Lee JH, Kwon M, Lim WY, Yoo CR, Yoon Y, Han D, et al. YAP inhibits HCMV replication by impairing STING-mediated nuclear transport of the viral genome. PLoS Pathog. 2022;18:e1011007. https:\/\/doi.org\/10.1371\/journal.ppat.1011007.","journal-title":"PLoS Pathog"},{"key":"3618_CR40","doi-asserted-by":"publisher","unstructured":"Zhang H, Cui M, Tang D, Wang B, Liang G, Xu C, et al. Localization of cancer cells for subsequent robust photodynamic therapy by ROS responsive polymeric nanoparticles with anti-metastasis complexes NAMI-A. Adv Mater. 2024;36: e2310298. https:\/\/doi.org\/10.1002\/adma.202310298","DOI":"10.1002\/adma.202310298"},{"key":"3618_CR41","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1039\/d4ra00352g","volume":"14","author":"K Li","year":"2024","unstructured":"Li K, Tian S, Sun K, Su Q, Mei Y, Niu W. ROS-responsive polyprodrug micelles carrying suicide genes in combination with chemotherapy and gene therapy for prostate cancer treatment. RSC Adv. 2024;14:5577\u201387. https:\/\/doi.org\/10.1039\/d4ra00352g.","journal-title":"RSC Adv"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03618-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:02:23Z","timestamp":1790388143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03618-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":41,"alternative-id":["3618"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03618-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GL is a founder of Hangzhou Gongchu Biotechnology Co., Ltd. A patent related to oncolytic vaccinia viruses expressing STRIP shRNA was applied for by Hangzhou Gongchu Biotechnology Co., Ltd.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The research protocols used in mouse experiments were approved by the Animal Ethics and Welfare Committee of Zhejiang Sci-Tech University (No. 202406071, No. 202110302-1). The nonhuman primate experiments in this study were carried out according to the legal and regulatory requirements of Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of National Center for Safety Evaluation of Drugs (No. IACUC-2020-053).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}